Quick Answer
Inhibitor Therapeutics, Inc. reported Cash And Cash Equivalents At Carrying Value of $2.38 million for the year ending 2025.
- Inhibitor Therapeutics, Inc. showed a decrease of -57.6% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from Inhibitor Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 26, 2026.
- XBRL data for this metric is available from 2011 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2012: $923.4 thousand | Q1 2013: $776.5 thousand | Q2 2013: $1.1 thousand | Q3 2013: $112.00 | Q1 2014: $456.00 | Q2 2014: $271.2 thousand | Q3 2014: $375.9 thousand | Q1 2015: $84.0 thousand | Q2 2015: $1.89 million | Q3 2015: $1.24 million | Q1 2016: $118.6 thousand | Q2 2016: $4.62 million | Q3 2016: $3.55 million | Q1 2017: $2.34 million | Q2 2017: $1.64 million | Q3 2017: $887.4 thousand | Q1 2018: $1.57 million | Q2 2018: $795.8 thousand | Q3 2018: $1.44 million | Q1 2019: $1.13 million | Q2 2019: $2.03 million | Q3 2019: $1.37 million | Q1 2020: $302.7 thousand | Q2 2020: $137.3 thousand | Q3 2020: $36.7 thousand | Q1 2021: $84.2 thousand | Q2 2021: $93.7 thousand | Q3 2021: $53.3 thousand | Q1 2022: $36.4 thousand | Q2 2022: $24.9 thousand | Q3 2022: $53.1 thousand | Q1 2023: $10.78 million | Q2 2023: $10.10 million | Q3 2023: $9.54 million | Q1 2024: $7.68 million | Q2 2024: $7.10 million | Q3 2024: $6.38 million | Q1 2025: $4.32 million | Q2 2025: $3.74 million | Q3 2025: $2.98 million.
- Over the full 15 years of available data (2011 to 2025), Inhibitor Therapeutics, Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 79.7%.
- Historical annual values: Fiscal year 2025: $2.38 million | Fiscal year 2024: $5.61 million | Fiscal year 2023: $8.84 million | Fiscal year 2022: $11.95 million | Fiscal year 2021: $30.6 thousand | Fiscal year 2020: $75.1 thousand | Fiscal year 2019: $803.8 thousand | Fiscal year 2018: $1.11 million | Fiscal year 2017: $344.1 thousand | Fiscal year 2016: $6.89 million | Fiscal year 2015: $601.4 thousand | Fiscal year 2014: $365.2 thousand | Fiscal year 2013: $217.00 | Fiscal year 2012: $857.7 thousand | Fiscal year 2011: $1.32 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: